A Phase I/ II Study of Fragmented Autoantigen Stimulated T-cell-immunotherapy Combined with Radiotherapy (FAST-CR)

Phase 0 Not yet recruiting 154 enrolled Fengming Kong Peking University · collab The University of Hong Kong-Shenzhen Hospital · collab

RandomizedParallel-groupSingle-blindTreatment

Summary

Evaluation and exploration of the phase I/II clinical safety and efficacy of personalized FAST(Radiation fueled antigens stimulated T-cell immunotherapy )cancer vaccine combined with radiotherapy.

Timeline

Start: 2025-03-25
Primary completion: 2028-03-01
Completion: 2028-03-01

Publications

Li Y, Chen H, Shen Q, Liu Y, Li P, Ma Y, Wang Y, Li S, Yan X, Liu L, Shuai J, Wu M, Ouyang Q, Kong FS, Yang G. Fragment Autoantigens Stimulated T-Cell-Immunotherapy (FAST) as a Fast Autologous Cancer Vaccine. Adv Sci (Weinh). 2025 Jul;12(26):e2502937. doi: 10.1002/advs.202502937. Epub 2025 Mar 26.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Fragment Autoantigens Stimulated T-Cell-Immunotherapy	Vaccine	—	—

A Phase I/ II Study of Fragmented Autoantigen Stimulated T-cell-immunotherapy Combined with Radiotherapy (FAST-CR)

Summary

Timeline

Publications

Drugs

Indications